- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Vor Biopharma: Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| Mi | Vor Biopharma: Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data | 102 | GlobeNewswire (Europe) | Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms 100% of patients on telitacicept for 48 weeks achieved =2-point Myasthenia Gravis Activities... ► Artikel lesen | |
| Di | Vor Biopharma Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.10. | Vor Biopharma: Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren's Disease | 2 | GlobeNewswire (USA) | ||
| 17.10. | Vor Biopharma: Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology's Kidney Week 2025 | 141 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data... ► Artikel lesen | |
| VOR BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 16.10. | Vor Biopharma: Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine | 3 | GlobeNewswire (USA) | ||
| 15.10. | Baird upgrades Vor Biopharma stock rating to Outperform on telitacicept potential | 2 | Investing.com | ||
| 14.10. | Vor Bio's Collaborator Delivers Positive Results For Telitacicept In Autoimmune Disorder That Impacts Tears | 1 | Benzinga.com | ||
| 14.10. | Vor Biopharma stock rises after positive Phase 3 results for Sjögren's treatment | 1 | Investing.com | ||
| 14.10. | Vor Biopharma: Aktie legt nach positiven Phase-3-Studiendaten zu Sjögren-Behandlung zu | 2 | Investing.com Deutsch | ||
| 14.10. | Vor Bio rises after partner RemeGen succeeds in Sjögren's disease study | 1 | Seeking Alpha | ||
| 03.10. | Vor Biopharma: Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 101 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on September... ► Artikel lesen | |
| 29.09. | Vor Bio to present telitacicept data for Sjögren's disease at ACR meeting | 3 | Investing.com | ||
| 29.09. | Vor Biopharma: Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren's Disease Clinical Study at ACR Convergence 2025 | 4 | GlobeNewswire (USA) | ||
| 25.09. | Vor Biopharma stock drops after filing to register warrant shares | 3 | Investing.com | ||
| 25.09. | Vor Biopharma-Aktie fällt nach Anmeldung von Aktien aus Optionsscheinen | 2 | Investing.com Deutsch | ||
| 24.09. | Vor Biopharma registers 51M shares for resale linked to RemeGen deal and PIPE financing | 1 | Seeking Alpha | ||
| 24.09. | Vor Biopharma Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 24.09. | Vor Biopharma upgraded to Buy at Stifel on telitacicept prospects | 2 | Seeking Alpha | ||
| 24.09. | Stifel upgrades Vor Biopharma stock to Buy on telitacicept prospects | 1 | Investing.com |
1 2 3 4 5 Weiter >>
92 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EDITAS MEDICINE | 2,717 | +1,19 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,034 | +15,31 % | SOL Global Investments Corp.: SOL Global Announces Change of Auditor | Toronto, Ontario--(Newsfile Corp. - October 15, 2025) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company") today announce that it has changed its auditor... ► Artikel lesen | |
| TRINITY BIOTECH | 1,010 | 0,00 % | Trinity Biotech plc: Trinity Biotech Welcomes Perceptive Advisor's Indication of Potential Debt-to-Equity Conversion - Strengthening Balance Sheet and Supporting Growth | ||
| FATE THERAPEUTICS | 1,183 | -0,13 % | FATE THERAPEUTICS INC - 8-K, Current Report | ||
| ARCTURUS THERAPEUTICS | 10,030 | +4,26 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| OVID THERAPEUTICS | 1,270 | +1,60 % | Ovid Therapeutics Inc.: Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds | NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant... ► Artikel lesen | |
| EQUILLIUM | 1,206 | +4,15 % | Equillium, Inc.: Equillium Announces Leadership and Corporate Updates | LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 11,490 | +1,32 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific | 4DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years for development activities supporting global registration... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 16,820 | +2,87 % | Regencell Bioscience Holdings Ltd - 20-F, Annual and transition report of foreign private issuers | ||
| GENERATION BIO | 5,400 | -0,55 % | Generation Bio Co.: Generation Bio Announces CEO Transition | • Geoff McDonough, MD to step down as CEO & President and become Chair of the Company's Board of Directors • Current Chief Legal Officer Yalonda Howze, JD named Interim CEO & President CAMBRIDGE,... ► Artikel lesen | |
| CABALETTA BIO | 3,625 | +47,66 % | Cabaletta Bio Reports Positive Rese-cel Data Across Myositis, SSc, and SLE Trials | ||
| LONGEVERON | 0,831 | +0,35 % | Longeveron Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect | ||
| PROKIDNEY | 3,060 | -0,49 % | ProKidney: Hoffnung für Patienten, Chance für Investoren | Die Forschung im Bereich der Nierenerkrankungen entwickelt sich rasant, und neue Therapieansätze rücken in den Fokus von Investoren und Fachwelt. Besonders spannend ist die Frage, ob ProKidney mit seiner... ► Artikel lesen | |
| ATHIRA PHARMA | 4,145 | 0,00 % | Athira Pharma, Inc.: Athira Pharma Announces Reverse Stock Split | BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. ("Athira" or "Company") (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore... ► Artikel lesen | |
| BOLT PROJECTS | 2,430 | +4,29 % | Pre-market Movers: Sonoma Pharmaceuticals, Bolt Projects, Ibotta, TeraWulf, 180 Life Sciences | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green Sonoma Pharmaceuticals, Inc. (SNOA) is up over... ► Artikel lesen |
Das Unternehmen VOR BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,94 % bei einem Aktienkurs von 24,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VOR BIOPHARMA INC finden Sie auf Wallstreet Online.